ArticleMSMR2025
Vaccine-preventable outbreak of acute respiratory illness and pneumonia associated with adenovirus at a U.S. Marine Corps training center.
Article in MSMR, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Adenovirus outbreaks have long been a cause of acute respiratory disease, hospitalization, and death in otherwise young, healthy military recruits. The administration of oral, live attenuated adenovirus (AdV) vaccine against AdV types 4 and 7 has been critical in preventing outbreaks in this population.1-4 In early July 2024, a spike in recruit hospitalizations for AdV pneumonia was recognized at the Marine Corps Recruit Depot (MCRD) San Diego, and an outbreak investigation commenced. From July 1 through September 23, 2024, a total of 212 AdV cases, including 28 hospitalizations, were identified among trainees and staff. Non-pharmaceutical interventions, including aggressive environmental cleaning, separation of sick and well recruits, and masking, were implemented. The outbreak was not appreciably slowed, however, until AdV vaccine administration was advanced from day 11 to day 1 post-arrival of recruits to MCRD San Diego. This outbreak report demonstrates that early AdV vaccination for newly arriving recruits is an effective and essential step in preventing AdV morbidity and mortality in a recruit training setting. Despite the availability and widespread use of effective vaccines during recruit training, adenovirus outbreaks remain a significant threat to military recruits if the vaccine is not administered expediently, upon arrival to the recruit training center.
Indexed as
Identifiers
40773300PMC12360644What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.